Phosphatase News and Research

RSS

Almac, BioFocus partner to provide FLT assays

BioFocus and Almac have initiated a collaboration which will provide BioFocus customers with compound screening and profiling services using Almac's FLEXYTETM fluorescence lifetime assays.

28 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Discovery of potent class of anti-cancer compounds by Scripps Research and MIT scientists

Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds.

8 Mar 2011

Nitroglycerin ointment may help in improving older women’s bone health: Study

A new study has shown that nitroglycerin ointment, that is used for chest pain or angina can be beneficial in postmenopausal women in improving their bone density. In this group of women, the bone becomes increasingly weak and brittle and leads to easy fractures. The study showed that postmenopausal women who used it for 2 years showed a modest increase in bone mineral density and decrease in bone resorption (loss). The study was published in the February 23 issue of JAMA.

22 Feb 2011

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.

21 Feb 2011

RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma

Genentech, a member of the Roche Group, today announced that BRIM3, a Phase III clinical study of RG7204, met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

19 Jan 2011

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma, today announced that it has successfully completed a Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in juveniles with hypophosphatasia, a serious, rare metabolic bone disorder.

10 Jan 2011

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

Breast cancer breakthrough

A team of researchers, led by Dr Clare Fedele and Professor Christina Mitchell at Monash University, Australia, has made a significant discovery in breast cancer research that identifies a particular protein’s role in tumor growth. They have also devised a new antibody that can identify the protein and measure its presence in breast cancer tissue.

1 Dec 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

miR765 RNA may play a role in development of heart failure: Research

Researchers at the University of Cincinnati (UC) have found a potential genetic target for heart disease, which could lead to therapies to prevent the development of the nation's No. 1 killer in its initial stages.

18 Nov 2010

Colcrys safe for treating gout flares

Patients who experience gout flares can be treated safely with Colcrys (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

9 Nov 2010

Research identifies key regulators that control transmission of malaria parasite

Scientists at The University of Nottingham and the Wellcome Trust Sanger Institute near Cambridge have pin-pointed the 72 molecular switches that control the three key stages in the life cycle of the malaria parasite and have discovered that over a third of these switches can be disrupted in some way.

21 Oct 2010

Study finds IAP enzyme maintains normal microbial population in gastrointestinal system

An enzyme that keeps intestinal bacteria out of the bloodstream may also play an important role in maintaining the normal microbial population of the gastrointestinal system.

19 Oct 2010

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

At the American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting today, researchers report progress on two top eye disease challenges treating advanced "dry" age-related macular degeneration, and preventing blindness in people with diabetes.

18 Oct 2010

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Mayo Clinic, Arizona Cancer Center, and the Translational Genomics Research Institute (TGen).

29 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

New high throughput sequencing technology to identify genetic defects in rare diseases

The majority of rare diseases are hereditary. But despite significant progress in genome research, in most cases their exact cause remains unclear. The discovery of the underlying genetic defect is, however, a prerequisite for their definitive diagnosis and the development of innovative approaches to their treatment. Scientists at the Max Planck Institute for Molecular Genetics and the Institute of Medical Genetics at the Charit- Universit-tsmedizin - Berlin have succeeded in using a new process with which all of the genes in the human genome can be analysed simultaneously.

30 Aug 2010

New research could extend the life of donated organs

The fruit fly Drosophila melanogaster does boast a powerful genetic system making it an ideal organism to test a cool new discovery: how an enzyme regulates body energy levels. Shutting off this molecular thermostat could result in a newfound cold tolerance that has multiple applications, including extending the 24-hour window donated organs now have for optimum use.

20 Aug 2010

Injecting PAP may reduce chronic pain: Research

A study published in the Aug. 4, 2010 issue of the Journal of Neuroscience introduces an enzyme that could pack a big punch in the battle against chronic pain. Its name is prostatic acid phosphatase or PAP for short. According to researchers at the University of North Carolina at Chapel Hill, PAP blocks pain in animal models by siphoning off a molecule called PIP2—a critical component of the chemical cascade behind chronic pain.

5 Aug 2010